Study of Antihypertensive Treatment in Patients with High-normal Blood Pressure and Risk Factors (CHINOM)

Study of Antihypertensive Treatment in Patients with High-normal Blood Pressure and Risk Factors

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-10000848

Enrollment

Unknown

Registered

2010-04-14

Start date

2007-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with High-normal Blood Pressure and Risk Factors

Interventions

Group A:Telmisartan 40 mg once a day

Group B:Indapamide 1.5mg once every two days

Group C1:placebo half a pill once a day

Group C2:placebo half a pill once a day

Eligibility

Sex/Gender

All

Age

45 Years to 79 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. Age: 45-79 (male) or 50-79 (female) years old; 2. Blood pressure: 130=85cm, female>=80cm or overweight (BMI >25kg/m2); (2) TC>=220mg/dL or TG>=150mg/dL or HDL-C 65 years old.

Exclusion criteria

Exclusion criteria: 1. Diabetes mellitus (FPG>=7.0mmol/L and/or OGTT 2hPG>=11.1mmol/L); 2. Hypertensive patients (SBP 3 140 mmHg and/or DBP 3 90 mmHg); 3. Patients participating in any other studies within three months or concomitantly; 4. Presence of renal dysfunction, Cr >133 mmol/L, or BUN >14.2mmol/L; 5. Presence of hepatic dysfunction (AST and/or ALT is 3 times higher than normal limit); 6. Hypersensitivity to agents used in this study; 7. Stroke or myocardial infarction within 6 months of the enrollment; 8. Balloon dilatation of coronary arteries or bypass operation within 2 months prior to the study; 9. Presence of malignant tumors or other serious diseases; 10. Pregnant or lactating women; women in reproductive age not using recognized contraceptive methods; 11. Gout or serum uric acid higher than 8.0mg/dL; 12. Incapacity or unwillingness to sigh the informed consent; 13. Incapacity for follow up; 14. Other reasons that on the discretion of the investigators that not appropriate to participate into the study.

Design outcomes

Primary

Measure	Time frame
Combined cardiovascular event;	—

Secondary

Measure	Time frame
stroke, hospitalized TIA, MI, hospitalized angina, hospitalized heart failure, peripheral arterial disease, tumor, all cause death, renal function failure;Development of hypertension or onset of diabete;	—

Countries

China

Contacts

Public ContactLisheng Liu

llshypt@yahoo.com.cn+86 010 88204189

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026